Esperion to Participate in Needham 22nd Annual Virtual Healthcare Conference
Esperion (NASDAQ: ESPR) has announced that Sheldon Koenig, the company's president and CEO, will participate in a fireside chat at Needham's 22nd Annual Virtual Healthcare Conference on April 17, 2023, at 8:45 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Esperion (NASDAQ: ESPR) has announced that Sheldon Koenig, the company's president and CEO, will participate in a fireside chat at Needham's 22nd Annual Virtual Healthcare Conference on April 17, 2023, at 8:45 AM ET. This event will provide insights into the company's innovative approaches in treating cardiovascular and cardiometabolic diseases. Interested parties can register for the live webcast through the provided link. A recorded version will be available for 90 days post-event.
Details
News Market Reaction – ESPR
The recorded move for ESPR in the trading session of this news was -3.14%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ANN ARBOR, Mich., April 03, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will host a fireside chat at Needham’s 22nd Annual Virtual Healthcare Conference on Monday, April 17th, 2023 at 8:45 AM ET.
To register for the live webcast, follow this link.
A live audio webcast can be accessed on the investor and media section of the Esperion website at investor.esperion.com. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
ESPERION Therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on Twitter at twitter.com/EsperionInc.
Contact:
Corporate Communications
corporateteam@esperion.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.